Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6043 in Advanced/Metastatic Solid Tumors
NCT07415863Phase 2Recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6043 in solid tumor, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Dec 2024; status: recruiting.
02
Drugs
SYS6043
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07415863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07415863.